{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=obinutuzumab&page=12", "query": { "intervention": "obinutuzumab", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 192, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=obinutuzumab&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=obinutuzumab&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T14:21:14.542Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02296918", "title": "Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Prolymphocytic Leukemia" ], "interventions": [ { "name": "acalabrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2014-12-22", "completion_date": "2025-10-22", "has_results": false, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-24T14:21:14.542Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02296918" }, { "nct_id": "NCT05861050", "title": "Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Blastoid Variant Mantle Cell Lymphoma", "Mantle Cell Lymphoma", "Pleomorphic Variant Mantle Cell Lymphoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Glofitamab", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 50, "start_date": "2023-08-10", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-24T14:21:14.542Z", "location_count": 3, "location_summary": "Duarte, California • New York, New York • Salt Lake City, Utah", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05861050" }, { "nct_id": "NCT06252675", "title": "Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Glofitamab", "type": "BIOLOGICAL" }, { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Tumor Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "ClonoSeq Assay", "type": "DEVICE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "DEVICE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-06-11", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-24T14:21:14.542Z", "location_count": 4, "location_summary": "Davis, California • Los Angeles, California • San Diego, California + 1 more", "locations": [ { "city": "Davis", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06252675" }, { "nct_id": "NCT06978088", "title": "LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Small Lymphocytic Lymphoma", "CLL/SLL", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "LP-168", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zulfa Omer", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2025-06-01", "completion_date": "2034-06-01", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-10-24T14:21:14.542Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06978088" }, { "nct_id": "NCT01059630", "title": "A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 413, "start_date": "2010-04-30", "completion_date": "2018-11-30", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-10-24T14:21:14.542Z", "location_count": 33, "location_summary": "Mobile, Alabama • Casa Grande, Arizona • Rogers, Arkansas + 26 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Casa Grande", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Pleasant Hill", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01059630" }, { "nct_id": "NCT02631577", "title": "A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Follicular" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A) [TECENTRIQ]", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2015-12-31", "completion_date": "2020-10-07", "has_results": true, "last_update_posted_date": "2022-04-13", "last_synced_at": "2026-10-24T14:21:14.542Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Miami, Florida • Louisville, Kentucky + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Miami", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02631577" }, { "nct_id": "NCT06054776", "title": "Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Glofitamab", "type": "BIOLOGICAL" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-12-02", "completion_date": "2026-10-16", "has_results": false, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-10-24T14:21:14.542Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06054776" }, { "nct_id": "NCT07674810", "title": "A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Sonrotoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-12-31", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-24T14:21:14.542Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07674810" }, { "nct_id": "NCT05039619", "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Acetaminophen/paracetamol", "type": "DRUG" }, { "name": "Diphenhydramine hydrochloride (HCl)", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 40, "start_date": "2022-05-12", "completion_date": "2030-06-14", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-24T14:21:14.542Z", "location_count": 11, "location_summary": "Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05039619" }, { "nct_id": "NCT04277637", "title": "Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mature B-Cell Malignancies" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 437, "start_date": "2020-03-24", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-24T14:21:14.542Z", "location_count": 13, "location_summary": "Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04277637" } ] }